Studienlage · Detail
Gemischt
GRADE
Niedrig
99 Zitate
Stichproben = 182 Pat.
Dauer2 Jahre
KontrolleKein Cannabiskonsum
EndpunktÜbergang zur Psychose
Verblindungn.a.
DesignProspektive Kohortenstudie
Kernaussage
Lifetime-Cannabiskonsum erhöhte das Transitionsrisiko nicht generell, jedoch steigerten früher Beginn und häufiger Konsum das Risiko signifikant.
Zusammenfassung
n=182 Ultra-Hochrisiko-Personen (UHR) für Psychose, 2-Jahres-Follow-up. Frühzeitiger Cannabis-Beginn (<15 Jahre) und häufiger Gebrauch: Transition zu Psychose 25% vs. 5% bei seltenerem/späterem Gebrauch (χ²=10,971, p=0,001). Im Gesamtsample keine signifikante Risikoerhöhung durch Lebenszeitkonsum (12,7% vs. 18,8%, p=0,303); Risikosignal konzentriert sich auf frühzeitigen Intensivgebrauch.
P
PopulationPersonen mit Ultra-High-Risk (UHR) für Psychose, n=182 (104 männlich, 78 weiblich)
I
InterventionCannabiskonsum (Lifetime- und fortgesetzter Konsum), prospektiv erfasst
C
KontrolleKein Cannabiskonsum
O
OutcomeKein signifikanter Unterschied in der Transitionsrate zur Psychose zwischen Cannabiskonsumenten und Nie-Konsumenten (12,7% vs. 18,8%; p=0,303); jedoch erhöhte Transitionsrate bei frühem Beginn (<15 Jahre) und häufigem Konsum (25% vs. 5%; p=0,001)
Vertrauen in die Evidenz
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Gemischt
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
<h4>Background</h4>Cannabis use is associated with an increased risk of developing a psychotic disorder but the temporal relationship between cannabis use and onset of illness is unclear. The objective of this study was to assess prospectively the influence of cannabis use on transition to psychosis in people at ultra-high risk (UHR) for the disorder.<h4>Method</h4>Lifetime and continued cannabis use was assessed in a consecutively ascertained sample of 182 people (104 male, 78 female) at UHR for psychosis. Individuals were then followed clinically for 2 years to determine their clinical outcomes.<h4>Results</h4>Lifetime cannabis use was reported by 134 individuals (73.6%). However, most of these individuals had stopped using cannabis before clinical presentation (n=98, 73.1%), usually because of adverse effects. Among lifetime users, frequent use, early-onset use and continued use after presentation were all associated with an increase in transition to psychosis. Transition to psychosis was highest among those who started using cannabis before the age of 15 years and went on to use frequently (frequent early-onset use: 25%; infrequent or late-onset use: 5%; χ(2)1=10.971, p=0.001). However, within the whole sample, cannabis users were no more likely to develop psychosis than those who had never used cannabis (cannabis use: 12.7%; no use: 18.8%; χ(2)1=1.061, p=0.303).<h4>Conclusions</h4>In people at UHR for psychosis, lifetime cannabis use was common but not related to outcome. Among cannabis users, frequent use, early-onset use and continued use after clinical presentation were associated with transition to psychosis.
„Was dem Handeln im Weg steht, wird zum Weg.“